Chronic Lymphocytic Leukemia Clinical Trials in Dallas, Texas

7 studies are recruiting for chronic lymphocytic leukemia in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

   This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymph…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas

   Locations

   632 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04269902 on ClinicalTrials.gov

2. Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

   This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Baylor University Medical Center, Dallas, Texas

   Locations

   15 in total

   Run by

   Imugene Limited

   See if you can join NCT03666000 on ClinicalTrials.gov

3. A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

   The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituxi…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Texas Oncology Baylorcharles A Sammons Cancer Center, Dallas, Texas

   Locations

   195 in total

   Run by

   BeOne Medicines

   See if you can join NCT06943872 on ClinicalTrials.gov

4. A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

   The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Texas Oncology - Sammons Cancer Center, Dallas, Texas

   Locations

   11 in total

   Run by

   Curis, Inc.

   See if you can join NCT07271667 on ClinicalTrials.gov

5. A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

   Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and change in disease activity will be assessed. Venetocl…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Texas - Southwestern Medical Center /ID# 266528, Dallas, Texas

   Locations

   70 in total

   Run by

   AbbVie

   See if you can join NCT06428019 on ClinicalTrials.gov

6. Study of SGR-1505 in Mature B-Cell Neoplasms

   The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas Southwestern, Dallas, Texas

   Locations

   36 in total

   Run by

   Schrödinger, Inc.

   See if you can join NCT05544019 on ClinicalTrials.gov

7. Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

   This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UT Southwestern Medical Center, Dallas, Texas

   Locations

   45 in total

   Run by

   Kartos Therapeutics, Inc.

   See if you can join NCT04502394 on ClinicalTrials.gov